A Phase I Trial of a Vaccine Combining Tyrosinase/GP100/Mart-1 Peptides Emulsified With Montanide ISA 51 With ProGP for Patients With Resected Stages III and IV Melanoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Filgrastim-FLT-3 ligand fusion protein; Melanoma vaccine
- Indications Malignant melanoma
- Focus Adverse reactions
- 22 May 2014 Biomarkers information updated
- 28 Jul 2006 Status change
- 12 Oct 2005 New trial record.